An Introduction to Neuroendocrine Tumours
The management of NETs is challenging & very difficult to study, due to many centres lacking experience in their management, survival rates remaining low and the overall rarity of the tumours themselves. However, recent developments in tumour grading, diagnostic biomarkers, radionuclide imaging and the development of somatostatin analogues, molecular targeted therapies, locoregional therapy and immunotherapies have improved outcomes in NETs. Further studies aimed at understanding the pathogenesis of NETs remain an important unmet need.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Neuroendocrine Tumours Content
Individualizing care for gastroenteropancreatic neuroendocrine tumours
Watch leading experts involved in the care of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) discuss how recent advances have driven the personalization of treatment options.
- Apply the criteria for the diagnosis of GEP-NETs
- Evaluate the current and emerging treatment sequencing options for patients with GEP-NETs
- Summarize why quality of life is important in patients with GEP-NETs and the role of the multidisciplinary team
ASCO 2016 Nicola Fazio
Dr. Nicola Fazio explains the findings of the RADIANT-4 Trial and discusses mTOR inhibition in neuroendocrine tumors.
Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids
European Oncology & Haematology, 2015;11(2):100–4 DOI: https://doi.org/10.17925/EOH.2015.11.02.100
Neuroendocrine neoplasms (NENs) are a group of rare and heterogeneous malignancies that arise from neuroendocrine cells in most organs of the body. The presence, rather than absence of symptoms due to neuropeptides or hormones hypersecretion, distinguishes NENs in functioning and non-functioning tumours, respectively. The term NEN is used to denote any type of neuroendocrine malignancies, […]
Octreotide – A Review of its Use in Treating Neuroendocrine Tumours
European Oncology & Haematology, 2013;9(2):105–9 DOI: https://doi.org/10.17925/EOH.2013.09.2.105
Neuroendocrine tumours (NETs) is a collective term for a diverse range of neoplasms that arise from cells that originate in the endocrine and nervous systems and share common morphological and immunohistochemical features, including the presence of secretory granules. These tumours can secrete a variety of neuropeptides, which may or may not cause characteristic hormonal symptoms […]
Optimising Therapeutic Options for Patients with Advanced Pancreatic Neuroendocrine Tumours
European Oncology & Haematology, 2012;8(4):217-223 DOI: https://doi.org/10.17925/EOH.2012.08.4.217
Pancreatic neuroendocrine tumours (pNETs), also known as islet cell tumours, arise from the pancreatic islet of Langerhans and can be divided into functioning and non-functioning tumours based on whether they are associated with hormonal syndromes caused by excess hormone or peptide secretion. Functioning pNETs can be responsible for a variety of clinical syndromes: Zollinger-Ellison syndrome […]
Antitumour Effects of Somatostatin Analogues in the Treatment of Neuroendocrine Tumours
European Oncology & Haematology, 2012;8(3):156-160 DOI: https://doi.org/10.17925/EOH.2012.08.3.156
Neuroendocrine tumours (NETs) are rare neoplasms that arise from neuroendocrine cells which are present throughout the body. NETs may be classified as functioning or non-functioning and are further differentiated based on the site of primary origin, histologic grade (low, intermediate or high) and proliferation rate.1 Functioning NETs are characterised by excessive hormone production and release, […]
Neuroendocrine Gastroenteropancreatic Tumours – Current Views on Diagnosis and Treatment
European Oncology Review, 2005:90-2 DOI: https://doi.org/10.17925/EOH.2005.0.0.90
Introduction Neuroendocrine gastroenteropancreatic (GEP) tumours constitute less than 2% of all gastrointestinal (GI) malignancies. The incidence of the largest group of patients, those with small intestinal carcinoid tumours, is two to 2.4 per 100,000 inhabitants. The true incidence is probably underestimated due to sometimes vague clinical presentation and low awareness among physicians. The incidence in […]
Neuroendocrine Gastroenteropancreatic Tumors—Recent Update on Diagnosis and Treatment
US Oncology Review, 2005;1(1):71-5 DOI: https://doi.org/10.17925/OHR.2006.00.00.1f
Neuroendocrine gastroenteropancreatic (GEP) tumors constitute less than 2% of all gastrointestinal (GI) malignancies. The incidence of the largest group of patients, those with small intestinal carcinoid tumors, is two to 2.4 per 100,000 inhabitants.The true incidence is probably underestimated due to sometimes vague clinical presentation and low awareness among physicians. The incidence in autopsy series […]
Use of Plasma Octreotide Levels to Guide Sandostatin® LAR Dosing
US Oncological Disease, 2006;1(1):48-50 DOI: https://doi.org/10.17925/OHR.2006.00.01.48
Octreotide and Lanreotide Octreotide and lanreotide are currently the most widely used somatostatin analogs to date. They control symptoms by inhibiting the synthesis and secretion of peptides and amines associated with functional sst 2- positive tumors. Following sst 2 binding, inhibition of G-protein-associated signal transduction pathways block secretory vesicle exocytosis and, thus, the release of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!